SCHEDULE: Vanguard Discloses 5.01% Stake in Tango Therapeutics
Beneficial Ownership Report (Schedule 13G)
The Vanguard Group reported a 5.01% beneficial ownership stake in Tango Therapeutics Inc. as of December 31, 2025, alongside an internal realignment of its reporting structure.
Summary
- The Vanguard Group beneficially owns 6,750,977 shares of Tango Therapeutics Inc. Common Stock.
- This ownership represents 5.01% of the class of securities.
- Vanguard holds shared voting power over 742,606 shares and shared dispositive power over 6,750,977 shares.
- An internal realignment occurred within The Vanguard Group, Inc. on January 12, 2026, where it ceased performing portfolio management services or administering proxy voting.
- Certain subsidiaries or business divisions of Vanguard are expected to report beneficial ownership separately (on a disaggregated basis) following this realignment, pursuing the same investment strategies.
Sentiment
Score: 7
Explanation: StockSavvy.ai views this as a moderately positive signal, indicating significant institutional interest and a stable ownership base from a major asset manager, reinforcing the company's presence in institutional portfolios.
Positives
- Significant institutional ownership by The Vanguard Group, a major asset manager, indicates a degree of confidence in Tango Therapeutics.
- The stake of 5.01% confirms Tango Therapeutics as a holding within Vanguard's managed portfolios.
Negatives
- NA
Risks
- NA
Future Outlook
NA
Industry Context
StockSavvy.ai notes that the disclosure of a significant passive stake by a major institutional investor like The Vanguard Group in a biotechnology company such as Tango Therapeutics is a common occurrence, reflecting the inclusion of the company in broad market index funds or actively managed portfolios. This type of filing primarily signals institutional presence rather than a specific strategic investment move, which is typical for large asset managers with diversified holdings.
Stakeholder Impact
- Shareholders: The disclosure of a significant stake by The Vanguard Group may provide a level of confidence and stability, indicating institutional backing for Tango Therapeutics.
Key Dates
| Date | Description |
|---|---|
| 12/31/2025 | Date of event which requires the filing of this statement (beneficial ownership threshold met). |
| 01/12/2026 | Date of internal realignment within The Vanguard Group, Inc., affecting its portfolio management and proxy voting services. |
| 01/30/2026 | Date the Schedule 13G statement was signed and filed. |
Recommendation
holdThe disclosure of a significant passive stake by The Vanguard Group indicates institutional confidence in Tango Therapeutics. However, as a Schedule 13G filing, it primarily reports ownership and does not provide new operational or financial performance data to warrant a change from a neutral "hold" position, but rather reinforces existing institutional support.
Keywords
Tango Therapeutics, Vanguard Group, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Biotechnology, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.